THERAPY DOSSIER · th-c67956c3c7fe

Protectin DX

Drug · Protectin DX, a specialized pro-resolving lipid mediator (docosanoid); not returned by ChEMBL name search.

Evidence & regulatory context

Mechanism: Protectin DX, a specialized pro-resolving lipid mediator (docosanoid); not returned by ChEMBL name search.
Target: Not recorded
Injury models: Endotoxin/LPS
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 33098250 ↗2020Reported benefit

Protectin DX promotes epithelial injury repair and inhibits fibroproliferation partly via ALX/PI3K signalling pathway.

MixedEndotoxin/LPSC57BL/6n = n = 6 per group across four groups; in vitro three independ…Intraperitoneal200 ng per mouse in 0.1 mL normal saline in vivo; 1-100 nmo…After intratracheal LPS

Model: Endotracheal injection of LPS (E. coli 055:B5) 10 mg/kg in 30 uL, assessed at 6, 24, 48 and 72 h

Protectin DX reduced lung injury score, wet/dry ratio, BALF protein and cytokines, promoted alveolar type II cell proliferation and wound repair, reduced apoptosis and suppressed TGF-beta-driven fibroproliferation.

Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.

Loading the evidence…